Abstract: A method of reducing, or even eliminating, the tariffs, surcharges and long-distance charges that might be incurred for calls involving wireless switching centers in multiple regions (or countries) is disclosed. This is accomplished in the illustrative embodiment by trunking calls directly from the calling wireless switching center to the visiting wireless switching center, where advantageous, without trunking the call across a regional or political boundary as is done in the prior art.

Abstract: A stabilized fluid conductivity measurement system includes a threaded metal housing with an inner portion having two probes for contacting the fluid to be measured and having an outer portion in which electrical circuitry is mounted. The circuitry includes a balanced square wave generator providing excitation to a modified Wheatstone bridge, including first and second input excitation terminals, and first and second output terminals. Fixed resistances may be located in 3 arms of the Wheatstone bridge, and the fourth arm may have two resistances with an intermediate tap; and one of the two probes is connected to this tap while the other probe is connected to one of the input excitation points.

Abstract: Apparatus and a method for providing international numbers in order to implement international cellular roamer service. When a roamer registers, the Visitor Location Register (VLR) serving the roamer, queries the Home Location Register (HLR) record of the roamer. The HLR tests whether the VLR is in a foreign country. If so, the HLR provides numerical information, such as the roamer's billing number, in international form, including the country code of the HLR. Advantageously, the VLR is provided with international numbers where appropriate, and the roamer can be accommodated outside the roamer's home country.

Abstract: The invention provides isolated nucleic acids that encode human pp-GaNTase 10, and fragments thereof, vectors for propagating and expressing human pp-GaNTase 10 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel human pp-GaNTase 10 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human pp-GaNTase 10 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human pp-GaNTase 10 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the human pp-GaNTase 10 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode RGL3, and fragments thereof, vectors for propagating and expressing RGL3 nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel RGL3 isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human RGL3 nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human RGL3 gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the RGL3 nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode LCP, including two isoforms, and fragments thereof, vectors for propagating and expressing LCP nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel LCP isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising human LCP nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the human LCP gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the LCP nucleic acids, proteins, and antibodies of the present invention.

Abstract: The invention provides isolated nucleic acids that encode a human protein kinase domain-containing portein (STTK), and fragments thereof, vectors for propagating and expressing STTK nucleic acids, host cells comprising the nucleic acids and vectors of the present invention, proteins, protein fragments, and protein fusions of the novel STTK isoforms, and antibodies thereto. The invention further provides transgenic cells and non-human organisms comprising STTK nucleic acids, and transgenic cells and non-human organisms with targeted disruption of the endogenous orthologue of the STTK gene. The invention further provides pharmaceutical formulations of the nucleic acids, proteins, and antibodies of the present invention, and diagnostic, investigational, and therapeutic methods based on the STTK nucleic acids, proteins, and antibodies of the present invention.